Pfizer Inc. (PFE) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

Pfizer Inc. (PFE)

43rd Annual J.P. Morgan Healthcare Conference Call

January 13, 2025, 12:45 PM ET

Company Participants

Albert Bourla - Chairman & Chief Executive Officer

Conference Call Participants

Chris Schott - JPMorgan

Presentation

Chris Schott

Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting this fireside chat with Albert Bourla, Chairman and CEO of Pfizer. Albert, happy New Year. Thanks for joining us.

Albert Bourla

Happy New Year and happy New Year to everyone.

Chris Schott

I know you're going to make some opening comments and then we'll jump into the que...

SA Transcripts on Seeking Alpha | January 13, 2025

Pfizer’s bladder cancer treatment achieves main goal in late-stage trial

More on Pfizer

• Dividend Roundup: Why I Prefer Johnson & Johnson Over Pfizer
• Pfizer: A Step-By-Step Strategy Before Earnings
• Seeking Alpha | January 10, 2025

The CEOs Who Are Tearing Up the Policies Trump Hates

Companies seeking to benefit from campaign promises to cut regulations and taxes are ditching diversity and climate initiatives; “EVERYBODY WANTS TO BE MY FRIEND!!!”

Yahoo | January 10, 2025

Arvinas Shares Fall Amid Breast Cancer Drug Trial Update, CCO Departure

Arvinas (ARVN) shares fell 5.7% in recent Friday trading after the company outlined plans for a data

Yahoo | January 10, 2025

Court Reopens Challenge to Pfizer Fellowship Program Amid Diversity Debate

U.S. court reopens Pfizer fellowship lawsuit amid growing scrutiny of diversity programs

Yahoo | January 10, 2025

Pfizer must face lawsuit over diversity fellowship program, US court rules

(Reuters) -A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that challenged a Pfizer fellowship program designed to boost the pipeline of Black, Latino and Native American people in leadership positions at the drugmaker. At the urging of the group Do No Harm, a 2-1 panel of the New York-based 2nd U.S. Circuit Court of Appeals revisted a decision it issued last year holding the organization lacked legal standing to challenge the drugmaker's program in court.

Yahoo | January 10, 2025

Pfizer Reveals Encouraging Data From Pivotal Bladder Cancer Trial

On Friday, Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance for BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The study met its primary endpoint of event-free survival by investigator assessment, showing a clinically meaningful and statistically significant improvement with

Yahoo | January 10, 2025

AI, vaccine distrust, & the future of healthcare: Novartis CEO

Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis (NVS) CEO Vas Narasimhan. Narasimhan has led the drug giant since 2018, doing deals that have expanded the company’s pipeline in areas like heart disease and cancer. Still, Narasimhan is feeling pressure to bring the investments to the bottom line to jumpstart its stock price.  In the last year, Novartis shares have declined 6.69%. During that same timespan, the S&P 500 and Dow Jones Industrial Average have gained 22.8% and 12%, respectively. The iShares U.S. Healthcare ETF (IYH) is up slightly in the past year. The stock prices of Pfizer (PFE) and Moderna (MRNA) are down 8.5% and 61%, respectively in the past year. For full episo...

Yahoo | January 10, 2025

Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded Deal

FDA grants priority review tag to JNJ's nipocalimab BLA for gMG and asks for new warnings on GSK & PFE's RSV vaccine labels.

Yahoo | January 10, 2025

Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

NEW YORK, January 10, 2025--Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The study met its primary endpoint of event-free survival (EFS) by investigator assessment, demonstrating a c

Yahoo | January 10, 2025